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The purpose of this study was to assess the risk of abnormal anal cytology in women with
known genital squamous intraepithelial lesion. This study evaluated 200 women with and
without genital squamous intraepithelial lesion who were recruited for anal Pap smears.
Women  who had abnormal results on equally or over atypical squamous cells of undeter-
mined signiﬁcance were classiﬁed as having abnormal anal cytology. A multiple logistic
regression analysis (stepwise) was performed to identify the risk for developing abnormal
anal  cytology. Data were analyzed using the SPSS 20.0 program. The average age was 41.09
(±12.64). Of the total participants, 75.5% did not practice anal sex, 91% did not have HPV-
infected partners, 92% did not have any anal pathology, and 68.5% did not have anal bleeding.
More  than half (57.5%) had genital SIL and a signiﬁcant number developed abnormal anal
cytology: 13% in the total sample and 17.4% in women with genital SIL. A signiﬁcant asso-
ciation was observed between genital squamous intraepithelial lesion and anal squamous
intraepithelial lesion (PR = 2.46; p = 0.03). In the logistic regression model, women  having
genital intraepithelial lesion were more likely to have abnormal anal Pap smear (aPR = 2.81;p  = 0.02). This report shows that women with genital squamous intraepithelial lesion must
be  more closely screened for anal cancer.
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Anal and cervical cancers have many  similarities that include
association with human papillomavirus (HPV) infection,
occurrence in an epithelial transformation zone, and coexis-
tence with high-grade squamous intraepithelial lesions.1HPV has been observed in 99% of cervical cancers and
80–90% of anal cancers.2–4 It is likely that the pathogenesis
of anal cancer is similar to that of cervical cancer: that is, anal
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HPV infection, in conjunction with other yet to be determined
factors, leads to the development of high-grade anal intraep-
ithelial neoplasia (HGAIN), which is a probable precursor to
4,5hoo.com.br (A.K. Gonc¸alves).
Considering that programmatic screening for cervical can-
cer with cytology has been associated with considerably
decreased incidence and mortality rates of cervical cancer,6
e under the CC BY-NC-ND license. (http://creativecommons.org/
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nal cytology has been assessed as a screening method for
nal neoplasia in high-risk individuals in some countries such
s the USA.7
Subjects with abnormal anal screening cytology are
eferred for a high-resolution anoscopy (HRA) or colposcopic
valuation of the anus. In cases diagnosed with HGAIN
hrough directed biopsies, an ablation of HGAIN lesions must
e done.8
Regardless of the extensive data on cervical neoplasia and
PV infection in women, there are limited data on anal neo-
lasia, anal HPV infection, and cytology. The purpose of this
tudy was to assess the risk of abnormal anal cytology in
omen with known genital SIL.
This study, conducted at the LNRCC-Luis Antonio Hos-
ital (hospital for cancer in Rio Grande do Norte, Brazil),
ssessed 200 HIV-seronegative women (using enzyme-linked
mmunosorbent assay [ELISA] and Western blot), 115 with and
5 without genital SIL. The ﬁrst group of women had gen-
tal SIL diagnosed by cytology, genitoscopy, and biopsy, and
he second group of women presenting for cervical cancer
creening had no genital SIL, based on cytology (two negative
apanicolaou smears) and a negative genitoscopy. An expert
athologist reviewed the Papanicolaou tests and biopsies.
atients in use of immunosuppressive therapy, transplanted,
nd HIV-infected were excluded.
After obtaining written informed consent, each subject
rovided a detailed history of routine gynecologic health-
are and risk factors for the development of anal cytologic
bnormalities. A standardized questionnaire inquired about
istory of anal intercourse; number of sexual partners;
istory of sexually transmitted diseases; cervical cytologic
bnormalities; vulvar warts; cervical, vulvar, or vaginal
ancers; solid organ transplantation; chronic corticosteroid
Fig. 1 – Normal (left) and atypical squamous cells of un6;2 0(3):294–297 295
use; history of cigarette smoking; and drug and alcohol
use.
After administering the questionnaire and completing the
patient history, a visual examination of the lower genital
tract was performed, and samples were collected for cervical
and anal cytology. The anal Pap smear was collected using
a cytobrush, which was inserted 4 cm into the anal canal.
The cytobrush was rotated 360◦ in a cone-shaped area and
removed. The sample was then smeared onto a glass slide,
immediately ﬁxed in 95% ethyl alcohol and transported to
the laboratory. Papanicolaou staining was used for cytopatho-
logic diagnosis and any cytological ﬁnding from ASCUS was
considered abnormal (Fig. 1).
Statistical analysis with 95% conﬁdence intervals per-
formed using descriptive and inferential statistics. A dichoto-
mous variable of anal SIL was used to assess its association
with the other nominal variables using Chi-square and Fisher
exact test. A multiple logistic regression analysis (stepwise)
was performed to identify predictors independently associ-
ated with anal SIL. Data were analyzed using the SPSS 20.0
program, and the level of signiﬁcance was set at 5%. This
study was approved by the Ethics Research Committee of the
institution (CAAE 1 07769612.3.0000.5293).
The mean age for patients included in this study was 41.09
(±12.64). Most were nonwhite (56%) and nonsmokers (91.5%),
with up to eight years of school education (50.5%). Regarding
the description of contextual variables, 55.5% used oral con-
traceptives, 9% used condoms, 80% had already been pregnant
and of these 30% had had an abortion. The majority had up
to three partners (73.5%) and had not contracted other (con-
comitant) sexually transmitted infection (STI), besides HPV
(74%). More than half reported not practicing anal sex (75.5%),
91% had partners with no clinical evidence of HPV-induced
determined signiﬁcance in anal cytology (right).
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Table 1 – The risk of anal SIL in women with genital HPV induced lesions.
Variable Category Anal SIL PR CI 95% p aPRb aCI 95% pc value
Yes (%) No (%)
GSIL Yes  20 (17.4%) 95 (82.6%) 2.46 1.03–5.87 0.03a 2.81 1.16–6.79 0.02
No 6 (7.1%) 79 (92.9%)
Age Until 41 years 11 (11.3%) 86 (88.7%) 0.78 0.38–1.61 0.49
>41 years 15 (14.6%) 88 (85.4%)
Race White 8 (9.1%) 80 (90.9%) 0.57 0.26–1.24 0.14
Non White 18 (16.1%) 94 (83.9%)
Years of study <8 years 13 (12.9%) 88 (87.1%) 0.98 0.48–2.01 0.95
>8 years 13 (13.1%) 86 (86.9%)
Smoking Yes 1 (5.9%) 16 (94.1%) 0.43 0.06–2.98 0.362
No 25 (13.7%) 158 (86.3%)
Contraceptive
use
Yes 16 (12.6%) 111 (87.4%) 0.92 0.44–1.92 0.824
No 10 (13.7%) 63 (86.3%)
N. partner >3  18 (12.2%) 129 (87.8%) 0.81 0.37–1.75 0.59
>3 8 (15.1%) 45 (84.9%)
STD Yes 6 (11.3%) 47 (88.7%) 0.83 0.35–1.96 0.67
No 20 (13.6%) 127 (86.4%)
HPV partner Yes 4 (22.2%) 14 (77.8%) 1.84 0.71–4.75 0.22
No 22 (12.1%) 160 (87.9%)
Anal sex Yes 8  (16.3%) 41 (83.7%) 1.37 0.63–2.95 0.42
No 18 (11.9%) 133 (88.1%)
Drug user Yes 1 (20.0%) 4 (80.0%) 1.56 0.26–9.35 0.63
No 25 (12.8%) 170 (87.2%)
Anal disease Yes 1 (6.3%) 15 (93.8%) 0.46 0.07–3.18 0.40
No 25 (13.6%) 159 (86.4%)
Anal bleeding Yes 5 (7.9%) 58 (92.1%) 0.52 0.20–1.31 0.149
No 21 (15.3%) 116 (84.7%)
GSIL, genital squamous intraepithelial lesions; SIL, squamous intraepithelial lesion; PR, prevalence ration; CI, conﬁdence interval; aPR, adjusted
prevalence ration; aCI, adjusted conﬁdence interval; STD, sexually transmitted disease.
a Chi-square test.
b Association Pearson’s chi-square.
c Logistic regression.
lesions. 87.5% had not used drugs, and 96.5% denied bisexual
relations. A large percentage of the women did not report any
anal pathology (92%) or anal bleeding (68.5%). However, more
than half had low genital intraepithelial lesions (57.5%), and
a signiﬁcant number developed abnormal anal cytology: 13%
of the total sample and 17.4% among women with genital SIL.
Concerning the association between anal SIL and the socio-
economic and contextual variables, a signiﬁcant association
was only observed between genital SIL and anal SIL (PR = 2.46;
p = 0.03). There was no signiﬁcant association between anal
SIL and all other studied variables. In the logistic regres-
sion model, after adjusting for the variables age and partner
with HPV, women with genital intraepithelial lesions pre-
sented more  risk for abnormal anal Pap smear (aPR = 2.81;
p = 0.02) (Table 1). Abnormal anal cytology was observed in
11 patients with cervical high squamous intraepithelial lesion
(HSIL – NIC2 and 3), nine patients with cervical low squamous
intraepithelial lesion (LSIL – NIC1), and in six women with
inﬂammatory samples. However no differences were observed
between the HSIL and LSIL groups. Vulvar lesions (genital
warts) were found in four patients with LSIL – NIC1 cervical
samples.The anal Pap smear has been a beneﬁcial tool for early
detection of intra-anal dysplasia in patients at risk, such as
HIV-infected men  and women.9,10In this study, there was no difference in the sociodemo-
graphic characteristics of women with genital lesions and
women without HPV-associated genital lesions. Age and anal
sex were not signiﬁcantly associated with abnormal anal
cytology or anal HPV-induced lesions in the study group, which
is in contrast to past studies.11,12
Concerning prevalence, in this group we  found abnormal
anal cytology in 13% of the total sample and in 17.4% among
women with genital SIL. Earlier, Jacyntho et al.11 observed sim-
ilar rates comparing 184 women with known genital SIL and
76 controls without genital SIL. Anal intraepithelial neopla-
sia was observed in 32 (17.4%) of the 184 women with genital
SIL compared with two (2.6%) of the 76 controls without gen-
ital SIL.11 Tatti et al.,13 studying 481 immunocompetent and
immunosuppressed women with genital SIL, found a higher
prevalence of abnormal anal cytology (27.8%), probably due
to the inclusion of HIV-infected patients.12 Several studies
have reported that HIV-infected women have higher rates of
abnormal anal cytology and histopathology results than HIV-
uninfected women.10,13,14 These results suggest that mainly
in HIV-infected women, the presence of genital HPV-induced
lesions could predict a probable abnormal anal cytology.Considering that HPV infection is strongly linked with anal
cancer and usually considered a ﬁeld infection of the anogen-
ital tract, it is possible that women with a history of genital SIL
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ay be under a higher risk for anal cancer. Many large-scale
ancer registry studies support robust associations between
 history of genital SIL and cancers of the anus.15–17 In a
opulation-based cohort study, Edgren and Sparén15 evalu-
ted the risk of anal cancer in women with a later history of
IN3 by linking Swedish national registries with cancer reg-
stries. The incident rate ratio was 4.68 for women with prior
igh-grade cervical lesion when compared with those with no
ervical lesion. The risk was substantially elevated ﬁve years
fter the diagnosis for all ages.15
A recent study examined women with high-grade disease
deﬁned as in situ) or invasive cervical, vulvar, or vaginal can-
er. The authors identiﬁed a signiﬁcant association between
revious genital SIL and invasive cancers of the cervix, vulva,
agina, and anus.16
A large study examined the long-term risk trend for a
econd cancer among 104,760 women with cervical can-
er. Women with diagnosed cervical cancer had greater
isk of developing anal cancer than women in the general
opulation.17
In conclusion, there is powerful epidemiological evidence18
howing a raised risk of anal cancer in women with a pre-
ious history of in situ and invasive cancers of the cervix,
agina, and vulva compared with the general population. In
his study, we observed a higher risk for abnormal anal cytol-
gy in women with genital HPV-induced lesions, suggesting
hat these women must be more  closely screened for anal
ancer.
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